AI @ Pfizer

Pfizer pilots autonomous AI agents with human-in-the-loop feedback for procurement checks achieving higher accuracy in purchasing; AI-driven clinical trial recruitment enhances feasibility and cost efficiency; hosted large-scale AI Festival spreading AI fluency across 7 countries and 54 sessions, reflecting organization-wide AI transformation commitment.

• CPO Rising: Pfizer's Path to AI-Driven Procurement: From Automation to Intelligence

Pfizer continues to lead pharma AI innovation with a comprehensive approach embedding AI/ML in all areas from research to supply chain; launched “Power of Knowing” video series featuring Arianna Huffington to elevate AI literacy internally and externally.

• Pfizer Insights: Pioneering the Future of Healthcare: Pfizer's AI Advantage

Strategic collaboration expansion with AI-services provider XtalPi to augment small molecule discovery and materials science simulations; Pfizer announced $1.2 billion in cost savings attributed to AI-driven automation and internal digital process transformation; AI-powered patient programs successfully enhance customer experience globally.

• PR Newswire: XtalPi and Pfizer Expand Strategic Collaboration to Advance AI-Driven Drug Discovery

Introduction of a generative AI-powered consumer digital product for health queries; AI usage in manufacturing enhanced product yield by 10% and reduced cycle time by 25%; expanded generative chemistry AI collaboration with PostEra accelerates antibody-drug conjugate development and SARS-CoV-2 replication inhibitors, supported by up to $350 million investment.

• C&EN: Pfizer doubles down on AI partnership with antibody-drug conjugate startup PostEra

Pfizer reported cutting years from drug development timelines through AI-driven discovery and personalized medicine strategies; claims a 12% reduction in clinical trial failure rates using large datasets and predictive models; emphasis on AI integration across pipeline with partnerships like Tempus and internal ML Research Hub.

• Virtasant: Pfizer's AI Drug Discovery Cuts Years Off Development Time

Appointment of Berta Rodriguez-Hervas as Chief AI and Analytics Officer to accelerate Pfizer's global AI strategy; reports highlight AI's role in reducing time-to-market for medicines and transforming supply chain and R&D efficiency.

• Technology Magazine: New AI Chief at Pfizer to Boost Digital Innovation

Expansion of AI-driven drug discovery platforms in collaboration with research partner CeMM; recognized as industry leader in AI/ML for drug discovery; deployment of AI-powered compliance copilots enhancing market and consumer insights; focus on predictive modeling and early-stage drug candidate identification.

• Fierce Biotech: Pfizer collab with CeMM leads to new drug discovery AI methods

Launch of 'Charlie', a generative AI marketing platform integrated with NLP and recommendation algorithms, resulted in up to 5x content production increase and 2-3x faster approval processes; AI also advanced clinical trial data oversight and customer behavior insights.

• Digiday: With 'Charlie,' Pfizer is building a new generative AI platform for pharma marketing

Pfizer formalized its AI policy recognizing AI’s transformative potential and began leveraging generative AI across at least 17 use cases spanning scientific research to productivity enhancements.

• Pfizer: Policy Position on Artificial Intelligence
• CIO.inc: How Gen AI Is Helping Pfizer Change Healthcare Narrative

Pfizer intensified AI/ML efforts to bring transformative medicines to patients faster, indicating a strategic scale-up beyond pilot projects.

• BioSpace: Pfizer Doubles Down on AI/ML to Bring Transformative Medicines

Published AI use cases illustrating practical applications supporting Pfizer’s immediate business goals including R&D and marketing.

• Emerj AI Research: Artificial Intelligence at Pfizer - 3 Use Cases

Pfizer publicly highlighted AI's role in accelerating vaccine and medicine discovery, reflecting expanded use of AI and supercomputing in R&D pipelines.

• Pfizer Insights: Pfizer Is Using AI to Discover Breakthrough Medicines

Pfizer’s initial AI experiments centered on machine learning and natural language processing supported by IBM Watson, marking early augmented intelligence adoption primarily in drug discovery and safety monitoring.

• BioPharma Dive: Pharma and AI? Let's try augmented intelligence first